Wednesday, April 17, 2013

Strides Arcolab ink JV agreement with US based Pfenx for developing and commercializing biosmilar products

Strides Arcolab  ’s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market and the first product would be launched in 2015 or 2016.

The lead product for joint venture Interferon beta-1b, a biosimilar to Betaseron, indicated for relapsing, remitting and secondary-progressive forms of multiple sclerosis and the product will commence human clinical trials by Q4

Enter your email address:


Delivered by FeedBurner